Viet Nam

Population 2018: 96 million

### Tuberculosis Profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>174 (111–251)</td>
<td>182 (116–263)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>6 (3.8–6.6)</td>
<td>6.2 (4–9)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>8.6 (5.4–13)</td>
<td>9.1 (5.7–13)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>11 (6.7–15)</td>
<td>11 (7–16)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>2.2 (1.4–3.2)</td>
<td>2.3 (1.5–3.4)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 3.6% (3.4–3.8)
- Previously treated cases: 17% (17–18)

#### TB case notifications, 2018

- Total new and relapse: 99,658
- % tested with rapid diagnostics at time of diagnosis: 20%
- % with known HIV status: 85%
- % pulmonary: 80%
- % bacteriologically confirmed: 70%
- % children aged 0–14 years: 2%
- % women: 27%
- % men: 71%
- Total cases notified: 102,171

#### Universal health coverage and social protection

- TB treatment coverage ( notified/estimated incidence), 2018: 57% (40–90)
- TB patients facing catastrophic total costs, 2016: 63% (58–67)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018: 8% (4–12)

#### Notified cases by age group and sex, 2018

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-4</td>
<td>10000</td>
<td>0</td>
<td>20000</td>
</tr>
<tr>
<td>5-14</td>
<td>20000</td>
<td>0</td>
<td>30000</td>
</tr>
<tr>
<td>15-24</td>
<td>30000</td>
<td>0</td>
<td>40000</td>
</tr>
<tr>
<td>25-34</td>
<td>40000</td>
<td>0</td>
<td>50000</td>
</tr>
<tr>
<td>35-44</td>
<td>50000</td>
<td>0</td>
<td>60000</td>
</tr>
<tr>
<td>45-54</td>
<td>60000</td>
<td>0</td>
<td>70000</td>
</tr>
<tr>
<td>55-64</td>
<td>70000</td>
<td>0</td>
<td>80000</td>
</tr>
<tr>
<td>65+</td>
<td>80000</td>
<td>0</td>
<td>90000</td>
</tr>
</tbody>
</table>

#### Treatment success rate and cohort size

- New and relapse cases registered in 2017: 92% (102,193)
- Previously treated cases, excluding relapse, registered in 2017: 87% (2,983)
- HIV-positive TB cases registered in 2017: 79% (3,002)
- MDR/RR-TB cases started on second-line treatment in 2016: 68% (2,450)
- XDR-TB cases started on second-line treatment in 2016: 68% (28)

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 39%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 22% (21–25)

#### TB financing, 2019

- National TB budget (US$ millions): 72
- Funding source: 14% domestic, 24% international, 62% unfunded

---

© Ranges represent uncertainty intervals
- MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
- Calculated for pulmonary cases only
- Includes cases with unknown previous TB treatment history
- Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-03-26

Data: www.who.int/tb/data